AstraZeneca has announced plans to spend $100 million expanding its Sydney, Australia facility, a move it says will add 60 jobs and boost exports to more than $2.4 billion over the next four years.
The investment will fund three specialized production lines at the North Ryde facility for innovative respiratory medicines. Each production line has the capacity to produce over 70 million units per year of asthma treatment, Pulmicort Respules.
AstraZeneca predicts that by 2025 its Australian site will be producing over one billion respules.